 |
 |
 |
|
The DOL-ART Cohort: providing evidence from real world data -Use of Dolutegravir-based regimens in routine clinical care in Germany
|
|
|
Reported by Jules Levin
HIV Glasgow 2016 23-26
Postel N.1, Mueller M.2, WyenC.3, Brust J.4,Stoehr A.5, GlaunsingerT.6, Scholten S.7, Rausch M.8, WestermayerB.9, Herrmann M.10, Walli RK.10
1prinzmed, Munich; 2Gemeinschaftspraxis, Stuttgart; 3Praxis am Ebertplatz, Cologne; 4Onkologie Praxis, Mannheim; 5IFI-Institut, Hamburg; 6Praxis PrenzlauerBerg, Berlin; 7Praxis Hohenstaufenring, Cologne; 8Ärztezentrum Nollendorfplatz, Berlin; 9GlaxoSmithKline, Munich, 10ViiV Healthcare, Munich




|
|
|
 |
 |
|
|